718 related articles for article (PubMed ID: 28650000)
1. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
[TBL] [Abstract][Full Text] [Related]
2. Preclinical safety and efficacy of andexanet alfa in animal models.
Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB
J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477
[TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
Abdulrehman J; Eikelboom JW; Siegal DM
Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083
[TBL] [Abstract][Full Text] [Related]
4. Andexanet Alfa: First Global Approval.
Heo YA
Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
[TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
[TBL] [Abstract][Full Text] [Related]
6. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
Sartori M; Cosmi B
J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
[TBL] [Abstract][Full Text] [Related]
7. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
8. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Milling TJ; Kaatz S
Am J Med; 2016 Nov; 129(11S):S80-S88. PubMed ID: 27575436
[TBL] [Abstract][Full Text] [Related]
10. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
11. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Rogers KC; Finks SW
Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385
[TBL] [Abstract][Full Text] [Related]
12. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
13. [Andexanet alfa (ONDEXXYA
Yajima T; Higashimori M; Takata C; Sasabe T
Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
[TBL] [Abstract][Full Text] [Related]
14. Reversal agents for non-vitamin K antagonist oral anticoagulants.
Levy JH; Douketis J; Weitz JI
Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
[TBL] [Abstract][Full Text] [Related]
15. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
Kalathottukaren MT; Creagh AL; Abbina S; Lu G; Karbarz MJ; Pandey A; Conley PB; Kizhakkedathu JN; Haynes C
Blood Adv; 2018 Aug; 2(16):2104-2114. PubMed ID: 30135185
[TBL] [Abstract][Full Text] [Related]
16. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
Kaide CG; Gulseth MP
J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
[TBL] [Abstract][Full Text] [Related]
17. Andexanet alfa for the reversal of factor Xa inhibitors.
Favresse J; Hardy M; van Dievoet MA; Sennesael AL; Douxfils J; Samama CM; Vornicu O; Dincq AS; Lessire S; Mullier F
Expert Opin Biol Ther; 2019 May; 19(5):387-397. PubMed ID: 30974977
[TBL] [Abstract][Full Text] [Related]
18. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
19. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
[TBL] [Abstract][Full Text] [Related]
20. Andexanet Alfa, the Possible Alternative to Protamine for Reversal of Unfractionated Heparin.
Maneno JN; Ness GL
Ann Pharmacother; 2021 Feb; 55(2):261-264. PubMed ID: 32667214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]